Catalog3 refs
AOD-9604
MetabolicMetabolic & Weight LosstherapeuticFat Loss PeptideWeight LossResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Circulation
Overview
AOD-9604 (Advanced Obesity Drug 9604) is a modified 16-amino-acid fragment of human growth hormone, corresponding to the C-terminal region (amino acids 176-191) with the addition of a tyrosine residue at the N-terminus. It was specifically engineered to isolate the lipolytic (fat-burning) properties of growth hormone while eliminating its growth-promoting and diabetogenic effects. AOD-9604 has received GRAS (Generally Recognized as Safe) status from the FDA for use as a food ingredient.
Primary Uses
Anti-obesity / fat reduction
Promoting lipolysis and fat oxidation
Stimulating breakdown of stored triglycerides in adipose tissue
Increasing β3-adrenergic receptor expression in adipose tissue
Fat loss
Weight loss
Targeted lipolysis
Cartilage repair
Osteoarthritis and joint health
Body-composition studies
Lipolysis and adipocyte biology
Metabolic syndrome models
Weight-management research
Cartilage regeneration
Lipolysis enhancement
Lipogenesis inhibition
Osteoarthritis support
lipolysis
Lipolysis promotion
Anti-obesity
Protocol Reference
Dose
300 mcg daily (or 250 mcg BID)
Frequency
Once Or Twice Daily, Fasted
Half-life
~30 Minutes
Route
Subcutaneous
Evidence
Mixed Evidence / Preclinical / Phase 2 clinical trials completed; FDA GRAS status / Well Studied / Limited clinical evidence / Clinical trials completed - did not achieve FDA approval; Phase IIb failed to beat placebo on primary endpoint (disputed)
Research References· 22
Research Models
HumanMouseOvineRatanimal
Also in Metabolic